Marshall Wace, LLP Curis Inc Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $489,868 - $1.68 Million	-689,956 Reduced 47.63%	758,721 $743,000
Q1 2022 May 16, 2022	BUY	$2.31 - $5.13 $3.35 Million - $7.43 Million	1,448,677 New	1,448,677 $3.45 Million
Q2 2021 Aug 13, 2021	SELL	$7.45 - $16.27 $467,606 - $1.02 Million	-62,766 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$8.78 - $12.8 $1.05 Million - $1.52 Million	-119,080 Reduced 65.48%	62,766 $711,000
Q4 2020 Feb 16, 2021	BUY	$1.08 - $8.2 $196,393 - $1.49 Million	181,846 New	181,846 $1.49 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.